Platinum(IV) organometallics I. Syntheses of trans-di(carboxylato)ethane-1,2-diamine-cis-bis(pentafluoro-phenyl)platinum(IV) complexes and the X-ray crystal structure of the n-butanoato derivative

Dynamics of the efficient cyclometalation of the undercoordinated organoplatinum complex [Pt(COD)(neoPh)]+ (neoPh = 2-methyl-2-phenylpropyl)

The cyclometalation reaction of [Pt(COD)(κ¹-neoPh)]⁺ (neoPh = 2-methyl-2-phenylpropyl) to [Pt(COD)(κ²-neoPh)] was studied experimentally and mechanistically using DFT and MD simulations.

Doltsinis N, Klein A. Reactions of the organoplatinum complex [Pt(cod) (neoSi)Cl] (neoSi = trimethylsilylmethyl) with the non-coordinating anions SbF6– and BPh4–

Reactions of the organoplatinum complex [Pt(cod)(neoSi)Cl] (neoSi = (trimethylsilylmethyl) with the Ag(I) salts of oxo or fluoride containing anions A– = NO3–, ClO4–, OTf – (trifluoromethanesulfonate) and SbF6– lead to the desired abstraction of the chlorido ligand and precipitation of AgCl. However, further reaction of the resulting Pt complexes [Pt(cod)(neoSi) (solvent)]+ with diverse N-heterocyclic ligands L such as pyridines, caffeine, and guanine did not yield the targeted complexes [Pt(cod)(neoSi)(L)](A) in most of the cases, but to extensive decomposition yielding [Pt(cod)(Me) (solvent)]+, thus transforming the neoSi into a methyl ligand. A detailed study on the reaction with SbF6– combining DFT calculations with NMR and MS revealed that Pt catalysed decomposition of SbF6‒ and fluorination of the neoSi silicon atom leading to FSiMe3. When reacting the parent complex with Ag(BPh4), the arylated derivative [Pt(cod)(neoSi)(Ph)] was obtained and characterised by multinuclear NMR, MS and single crystal XRD.

Synthesis and antiproliferative activity of a series of new platinum and palladium diphosphane complexes

New organometallic complexes [M(dppe)(R)₂] {where M = Pt or Pd, dppe = 1,2-bis(diphenylphosphano)ethane, and R = C₆F₄H-x (x = 6,5,4), C₆F₃H₂-3,5, C₆F₃H₂-5,6, C₆F₃H₂-3,6, C₆F₄(OMe)-4, and C₆F₄(cyclo-C₅H₁₀N)-4, the numbers x refer to the positions of the protons in the polyfluoroaryl ligands} were synthesised either through transmetalation from the dichlorido complexes [M(dppe)Cl₂] or through ligand exchange using [M(diene)Cl₂] precursor complexes with diene = 1,5-cyclooctadiene (cod) or 1,5-hexadiene (hex). Alternatively, [M(dppX)Cl(R)] complexes with dppX = dppm (1,1-bis(diphenylphosphano)methane), dppe, dppp (1,3-bis(diphenylphosphano)propane), and dppb (1,4-bis(diphenylphosphano)butane) were prepared in decarboxylation reactions from thallium(i) carboxylates Tl(O₂CR). The different preparative methods were compared in terms of yield and purity. Structural and spectroscopic data are reported for the new dppX- and diene-M(R)₂ complexes. Antiproliferative activity was investigated for these new complexes against the HT-29 (colon carcinoma) and MCF-7 (breast adenocarcinoma) cell lines, and the active compounds of this first series together with organometallic dppX or hex Pt^II or Pd^II complexes were then included in cell tests using L1210 (leukaemia cells) and the cisplatin-resistant L1210/DDP cell line. Remarkably, promising antiproliferative results were found for a few Pt^II and Pd^II complexes, while structurally closely related compounds were essentially nontoxic.

Oxidation of dimethylplatinum(II) complexes with malonyl peroxide derivatives

The reaction of the cyclic peroxides cyclobutane malonoyl peroxide and cyclopentane malonoyl peroxide to dimethylplatinum(II) complexes with the bidentate nitrogen donor ligand 4,4′-di-t-butyl-2,2′-bipyridine (bubpy) gave a mixture of the products of cis and trans oxidative addition, [PtMe2{(O2C)2C(C3H6)}(bubpy)] and [PtMe2{(O2C)2C(C4H8)}(bubpy)], respectively. The cis isomers exist with a chelating dicarboxylate ligand, forming a six-membered ring, while the trans isomers are thought to exist as oligomers, which may react with water or solvent to give complexes containing a monodentate dicarboxylate ligand. Equilibration of the product of cis oxidative addition, cis-[PtMe2{(O2C)2C(C3H6)}(bubpy)], with oxalic or phthalic acid to give equilibria with the oxalate cis-[PtMe2(O4C2)(bubpy)] or phthalate cis-[PtMe2{(O2C)2C6H4}(bubpy)] derivative, respectively, indicated the expected sequence of chelate stability oxalate > cyclobutane malonate > phthalate.

Chiral platinum(II) metallointercalators with potent in vitro cytotoxic activity

Four platinum(II) metallointercalating complexes of 1,10-phenanthroline (phen) with the chiral ancillary ligands trans-R,R- and trans-S,S-1,2-diaminocyclohexane (R,R- and S,S-dach, respectively), and N,N'-dimethyl-R,R- and N,N'-dimethyl-S,S-1,2-diaminocyclohexane (Me(2)-R,R-dach and Me(2)-S,S-dach, respectively) have been synthesised and characterised. The crystal structure of [Pt(Me(2)-S,S-dach)(phen)](ClO(4))(2)1.5 H(2)O (C(20)H(26)Cl(2)N(4)O(9.5)Pt) has been determined; orthorhombic, space group P2(1)2(1)2(1)(No. 19), a=23.194(8), b=25.131(9), c=8.522(3) A. In vitro cytotoxic assays (IC(50)) in the human bladder cancer cell line 5637 and in the murine leukemia L1210 cell line revealed that [Pt(S,S-dach)(phen)](ClO(4))(2) (0.091 and 0.13 microM, respectively) and [Pt(R,R-dach)(phen)](ClO(4))(2) (0.54 and 1.50 microM, respectively) were more cytotoxic than cisplatin (0.31 and 0.50 microM, respectively) and considerably more cytotoxic than their methylated counterparts, [Pt(Me(2)-R,R-dach)(phen)](ClO(4))(2) and [Pt(Me(2)-S,S-dach)(phen)](ClO(4))(2) (both>23 microM). Chiral discrimination for [Pt(S,S-dach)(phen)](ClO(4))(2) over its R,R-enantiomer was observed in all 13 cancer cell lines investigated. Moreover, [Pt(S,S-dach)(phen)](ClO(4))(2) was more active than cisplatin in all cell lines tested and shows only partial cross-resistance to cisplatin in two cisplatin resistant cell lines.

Preparation and cell growth inhibitory activity of [PtR(2)L(2)] (R=polyfluorophenyl, L(2)=diene, cyclohexane-1,2-diamine (chxn) or cis-(dimethyl sulfoxide)(2)) and the X-ray crystal structure of [Pt(C(6)F(5))(2)(cis-chxn)]

A range of [PtR(2)(chxn)] (R=C(6)F(5), o-HC(6)F(4), p-HC(6)F(4), p-MeOC(6)F(4) or 3,5-H(2)C(6)F(3); chxn=cyclohexane-1,2-diamine) and cis-[PtR(2)(dmso)(2)] (R=C(6)F(5), p-HC(6)F(4) or p-MeOC(6)F(4); dmso=dimethyl sulfoxide) complexes have been prepared from the corresponding [PtR(2)(diene)] (diene=cis,cis-cycloocta-1,5-diene (cod), hexa-1,5-diene (hex), norbornadiene (nbd) or dicyclopentadiene (dcy)) derivatives and have been spectroscopically characterized. A representative crystal structure of [Pt(C(6)F(5))(2)(cis-chxn)] was determined and shows a slightly distorted square planar geometry for platinum with chxn virtually perpendicular to the coordination plane. The biological activity against L1210 and L1210/DDP cell lines of these compounds together with the behaviour of other organoplatinum complexes, [PtR(2)L(2)] (L(2)=ethane-1,2-diamine (en) or cis-(NH(3))(2)) have been determined. Despite the use of relatively inert fluorocarbon anions as leaving groups, moderate-high cell growth inhibitory activity is observed. None of the fluorocarbon complexes displayed any cross resistance with cisplatin.

Platinum(IV) complexes with dipeptide. X-ray crystal structure, 195Pt NMR spectra, and their inhibitory glucose metabolism activity in Candida albicans

Three dipeptide complexes of the form K[Pt(IV)(dipep)Cl3] and two complexes of the form K[Pt(IV)(Hdipep)Cl4] were newly prepared and isolated. The platinum(IV) complexes containing the dipeptide were obtained directly by adding KI to H2[PtCl6] solution. The reaction using KI was rapidly completed and provided analytically pure yellow products in the form of K[Pt(dipeptide)Cl3] for H2digly, H2gly(alpha)-ala, H2alpha-alagly and H2di(alpha)-ala. The K[Pt(IV)(digly)Cl3] complex crystallizes in the monoclinic space group P2(1)/c with unit cell dimensions a = 10.540(3) A, b = 13.835(3) A, c = 8.123(3) A, beta = 97.01(2) degrees, Z = 4. The crystal data represented the first report of a Pt(IV) complex with a deprotonated peptide, and this complex has the rare iminol type diglycine(2-) coordinating to Pt(IV) with the bond lengths of the C2-N1 (amide) bond (1.285(13) A). The 195Pt NMR peaks of the K[Pt(IV)(dipep)Cl3] and the K[Pt(IV)(Hdipep)Cl4] complexes appeared at about 270 ppm and at about -130 ppm, respectively, and were predicted for a given set of ligand atoms. While the K[Pt(IV)(x-gly)Cl3] complexes, where x denotes the glycine or alpha-alanine moieties, were easily reduced to the corresponding platinum(II) complexes, the K[Pt(IV)(x-alpha-ala)Cl3] complexes were not reduced, but the Cl- ion was substituted for OH- ion in the reaction solution. The K[Pt(digly)Cl3] and K[Pt(gly-L-alpha-ala)Cl3] complexes inhibited the growth of Candida albicans, and the antifungal activities were 3- to 4-fold higher than those of cisplatin. The metabolism of glucose in C. albicans was strongly inhibited by K[Pt(digly)Cl3] and K[Pt(gly-L-alpha-ala)Cl3] but not by the antifungal agent fluconazole.

Reactions of C(6)F(5)Li with tetracyclone and 3-ferrocenyl-2,4, 5-triphenylcyclopentadienone: An (19)F NMR and X-ray crystallographic study of hindered pentafluorophenyl rotations

Tetracyclone, 2a, reacts with C(6)F(5)Li to yield 2-pentafluorophenyl-2,3,4,5-tetraphenylcyclopent-3-en-1-one, 7, and 5-hydroxy-5-pentafluorophenyl-1,2,3,4-tetraphenylcyclopentadiene, 8, as the result of 1,6 and 1,2 additions, respectively. In contrast, treatment of 3-ferrocenyl-2,4,5-triphenylcyclopentadienone, 2b, with lithiopentafluorobenzene leads to 4-ferrocenyl-4-pentafluorophenyl-2, 3,5-triphenylcyclopent-2-en-1-one, 9, and 5-hydroxy-5-pentafluorophenyl-2-ferrocenyl-1,3, 4-triphenylcyclopentadiene, 10, the products of 1,4 and 1,2 addition, respectively. The structures of 7-9 have been established by X-ray crystallography, and the barriers to rotation (19-21 kcal mol(-)(1)) of the pentafluorophenyl groups in 8-10 have been studied by variable-temperature (19)F NMR. Nucleophilic attack at the ferrocenyl-bearing carbon in 2b is rationalized in terms of a zwitterionic structure in which the positive charge of the "cyclopentadienyl cation" is delocalized onto the iron atom in the organometallic substituent.

Pd(II) complexes with polydentate nitrogen ligands. Molecular recognition and dynamic behavior involving Pd-N bond rupture. X-ray molecular structures of [[Pd(C6HF4)2](bpzpm)] and [[Pd(eta 3-C4H7)]2(bpzpm)] (CF3SO3)2 [bpzpm = 4,6-bis(pyrazol-1-yl)pyrimidine]

The ligands 4,6-bis(pyrazol-1-yl)pyrimidine (bpzpm) and 4,6-bis(4-methylpyrazol-1-yl)pyrimidine (Me-bpzpm) were synthesized and their reactions with some palladium derivatives explored. Mononuclear or dinuclear neutral or cationic complexes were obtained by reaction of the ligands with 1 or 2 equiv of Pd(C6XF4)2(cod) (cod = 1,5-cyclooctadiene; X = F, H) or the palladium fragment [Pd(eta 3-2-Me-C3H4)(S)2]+ (S = acetone). The reaction of the dinuclear derivatives with 1 equiv of the respective free ligand immediately led to the regeneration of the mononuclear complexes. Except in the case of the synthesis of [[Pd(C6HF4)2][Pd(C6F5)2](bpzpm)], where two similar metallic groups are present, all attempts to obtain dinuclear asymmetric complexes with two different palladium fragments failed. Instead, the dinuclear symmetric complexes were formed. This result could be considered as an example of molecular recognition with the ligand acting as a ditopic receptor. This behavior is comparable to chemical symbiosis but in this case applied to the ligand rather than to the metal center as occurs normally. The polyfluorophenyl rings are situated on average in a perpendicular orientation with respect to the coordination plane. Their restricted rotation results in several atropoisomers for the complexes with m-C6HF4. Different cross-reaction experiments were carried out, and these showed the mobility of the metallic fragments, with the more difficult process being that involving the more strongly bonded polyfluorophenyl palladium groups. By means of 1H NMR variable temperature studies, the interconversion of the two isomers of [[Pd(eta 3-C4H7)]2-(bpzpm)]Tf2 (Tf = CF3SO3) was analyzed. In the case of [[Pd(eta 3-C4H7)](bpzpm)]Tf the existence of two processes, an intramolecular apparent allyl rotation and an intermolecular exchange of the allylpalladium fragments, has been demonstrated. Different delta Gc++ values at the coalescence temperatures have also been determined. An X-ray single-crystal analysis was carried out on [[Pd(eta 3-C4H7)]2(bpzpm)]Tf2, which crystallizes in the monoclinic system, space group I2/m, with a = 9.368(2), b = 16.191(3), c = 20.228(6) A, beta = 101.26(3), and Z = 4. Compound [[Pd(C6HF4)2](bpzpm)] crystallized in the triclinic system, space group P1, with a = 8.845(6), b = 12.6609(9), c = 12.826(3) A, alpha = 88.45(2), beta = 74.36(3), gamma = 89.32(2), and Z = 2.

Modifying the properties of platinum (IV) complexes in order to increase biological effectiveness

The preparation of a series of novel Pt(IV) complexes containing the anionic polyfluoroaryl ligands, 2,3,5,6-tetrafluorophenyl (p-HC6F4), 2,3,5,6-tetrafluoro-4-methoxyphenyl (p-MeOC6F4) and pentafluorophenyl (C6F5) are described. The crystal structure of a representative complex, [Pt(p-MeOC6F4)2(O2CEt)2(en)] (en = ethane-1,2-diamine) was determined and confirms the trans arrangement of the carboxylato ligands. Reduction potentials of the series of complexes reveal that replacement of equatorial chloro ligands by polyfluoroaryl ligands makes reduction substantially more difficult. They also confirm previously reported trends in that complexes having axial carboxylato ligands are more readily reduced than those having axial hydroxo ligands. Reduction potentials and in vitro activities showed no obvious correlations. Moderate to high activity was observed for many complexes in the series, including some of those that were very difficult to reduce.